{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-063059","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2026-05-18T13:01:28+00:00","discovered_at":"2026-05-18T13:02:00.293371+00:00","generated_at":"2026-05-18T13:02:56.643202+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"MetaVia announces three late-breaking abstracts accepted for ADA 2026 poster presentations","bullets":["DA-1726 (GLP-1/glucagon dual agonist) Phase 1 Part 3 titration study data expected Q4 2026.","Vanoglipel (GPR119 agonist) preclinical combo data with resmetirom for MASH and metformin for T2D.","Presentations at ADA 2026 in New Orleans, June 5-8; posters available after event.","CEO notes DA-1726 potential as differentiated obesity treatment; vanoglipel broad liver/metabolic therapeutic potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-063059","json":"https://secwatch.observer/filing/0001104659-26-063059.json","markdown":"https://secwatch.observer/filing/0001104659-26-063059.md","text":"https://secwatch.observer/filing/0001104659-26-063059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926063059/0001104659-26-063059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926063059/mtva-20260518x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:02:56.643202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}